Abstract:Background Familial hypercholesterolemia is the elective clinical condition that deserves the maximal personalisation in lipid-lowering therapy, especially in the presence of statin intolerance. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors represent a promising approach to lower low-density lipoprotein (LDL) cholesterol. Methods We enrolled 18 patients (mean age 62 ± 8 years, 72% men) affected by heterozygous familial hypercholesterolemia and cardiovascular disease, with a history of statin… Show more
“…No adverse side effects were described. This observation confirms that apheresis leads to a dramatic reduction in lipid levels, in agreement with previous findings, 7 and that PCSK9 inhibitors can be considered a relevant and safe therapeutic alternative approach. 8…”
Section: From Lipoprotein Apheresis To Pcsk9 Inhibitorssupporting
“…No adverse side effects were described. This observation confirms that apheresis leads to a dramatic reduction in lipid levels, in agreement with previous findings, 7 and that PCSK9 inhibitors can be considered a relevant and safe therapeutic alternative approach. 8…”
Section: From Lipoprotein Apheresis To Pcsk9 Inhibitorssupporting
“…Sbrana et al enrolled 18 individuals, with a mean age of 62 years, with hypercholesterolemia, cardiovascular disease, and statin intolerance (Table I) (25). The efficiency of PCSK9 inhibitors was investigated.…”
“…However the need for six patients to undergo lipid apheresis shows that even with the availability of these powerful drugs, optimal treatment may require further interventions. 14 …”
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.